Stock listing
7VR Stock Price, News, Filings & Events — Celcuity Inc.
Selected listing: 7VR · GETTEX · EUR · DE
This page tracks Celcuity Inc.'s 7VR:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 7VR:GETTEX. 7VR:GETTEX is the stock-level entry point for investors researching Celcuity Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- 7VR:GETTEX
- Asset type
- Stock
- Market cap
- $4.33B
- Sector
- Health Technology
- Industry
- Medical Specialties
- Exchange
- GETTEX
- Currency
- EUR
Celcuity Inc. 7VR:GETTEX stock context
This page tracks Celcuity Inc.'s 7VR:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 7VR:GETTEX. 7VR:GETTEX is the stock-level entry point for investors researching Celcuity Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Celcuity Inc.
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
August 26, 2026
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines f...
July 30, 2026
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastat...
July 14, 2026
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
June 3, 2026
Celcuity Inc. earnings calls
Celcuity Inc. (CELC) Q2 2026 Earnings Call
August 13, 2026 · Replay with transcript and chapters
Celcuity Inc. (CELC) Q1 2026 Earnings Call
May 14, 2026 · Replay with transcript and chapters
Celcuity Inc. (CELC) Q4 2025 Earnings Call
March 25, 2026 · Replay with transcript and chapters
Celcuity Inc. (CELC) Q3 2025 Earnings Call
November 12, 2025 · Replay with transcript and chapters
Celcuity Inc. (CELC) Q2 2025 Earnings Call
August 14, 2025 · Replay with transcript and chapters
Celcuity Inc. (CELC) Q1 2025 Earnings Call
May 14, 2025 · Replay with transcript and chapters
Research Celcuity Inc.
Celcuity Inc. investor report
Review AI stock analysis and investor report context for 7VR:GETTEX.
Celcuity Inc. company profile
View the public company page for Celcuity Inc. on 6ix.
Celcuity Inc. news
Read company news and market updates connected to Celcuity Inc..
Celcuity Inc. investor events
Find investor webinars, events, and replay context for Celcuity Inc..
Alternate listings
CELC:NASDAQ
US · USD
Alternate listing for Celcuity Inc.; the primary context on this page is 7VR:GETTEX.
CELC:BOATS
US · USD
Alternate listing for Celcuity Inc.; the primary context on this page is 7VR:GETTEX.
7VR:TRADEGATE
DE · EUR
Alternate listing for Celcuity Inc.; the primary context on this page is 7VR:GETTEX.
7VR:FWB
DE · EUR
Alternate listing for Celcuity Inc.; the primary context on this page is 7VR:GETTEX.
7VR:MUN
DE · EUR
Alternate listing for Celcuity Inc.; the primary context on this page is 7VR:GETTEX.